Seizing Future Opportunities in the AI-Driven Transformation of the Biopharmaceutical Industry

Since the beginning of the 21st century, against the backdrop of transitioning from old to new growth drivers and policy support, a profound transformation represented by innovative technologies such as biomedicine and artificial intelligence is accelerating.

Amid this technological wave, countless innovative enterprises have emerged in an effort to seize the trend. However, the challenge lies inNew Drug DevelopmentAlwaysone of the most risky, complex, and time-consuming fields of technological research in human developmentI.。According to*Nature* (Nature) magazine data shows that aThe R&D cost of new drugs is approximately$2.6 billion, approximately 10 years in development, yet with a success rate of less than one in ten, whileArtificial intelligence technologies that have emerged in recent years are helping the industry address this issue.

This is because the advantage of artificial intelligence lies in its ability to screen for new therapeutic targets and novel drugs from massive datasets, thereby reducing the time and high costs associated with drug discovery.According toData from Exscientia’s company deck shows that, compared toTraditional new drug development costs nearly$200 billion in costs, with AI technology reducing R&D expenses by approximately 35%Cost and cycle time also from5 to 10 years shortened to 1-2 years.

On the other hand, thanks to the efforts of industry professionals,An increasing number of innovative therapies are transitioning from the laboratory to clinical application, and China has become one of the most active regions worldwide for clinical research in cell and gene therapy.According to the "Report on" released by China Business Industry Research InstituteThe 2021 Report on Market Prospects and Investment in China’s Biopharmaceutical Industry during the 14th Five-Year Plan period indicates that, with the implementation of the “dual circulation” strategy and the 14th Five-Year Plan in 2020, the market size of biologics in China is projected to exceed RMB 800 billion by 2025.

In terms of technical pathways, withThe progress and breakthroughs achieved by adoptive cell immunotherapy, represented by CAR-T, in fields such as oncology treatment have drawn significant attention from the medical community. In light of this trend,The Door to a New Wave of Industrialization in Cell and Gene Therapy Is Opening.

Certainly, the research and development (R&D) and industrialization of new drugs is an endeavor that requires collaborative support from multiple stakeholders. Therefore, both local governments and pharmaceutical R&D enterprises must proactively address the challenges posed by technological advancements and commercial competition, thereby delivering better solutions for patients.

In the Face of Trends,Hosted by the People's Government of Nanshan District, supported by the Shenzhen Talent Work Bureau and the Shenzhen Municipal Science and Technology Innovation Commission, organized by the Nanshan District Science and Technology Innovation Bureau, and co-organized by VCBeat“2021 Future Medical Technology Trends (Xili Lake) Forum” was held on October 14At Nanshan LongzhongConvened.The forum brought together national academicians, industry leaders, top-tier investors, and core resources from the medical technology innovation ecosystem, with topics focusing onAI-Driven Drug Discovery and Cell & Gene Therapy: Two Key Sectors Offering a Glimpse into the Future Trends of Medical Technology

Cross-Pollination and Integration: Technology-Driven Boom in the Biopharmaceutical Industry

Whether it isWhether it is AI-driven drug development or cell and gene therapy, both represent a major “convergence” of frontier sciences, requiring interdisciplinary cross-pollination and integration.

For example, in the field of AI-driven new drug development, interdisciplinary collaboration is required among computer science, biology, chemistry, and many other disciplines. The specific approach involves leveraging big data models—such as omics data, scientific literature databases, and clinical trial data—to enable AI technologies to perform inferential creativity. This facilitates a qualitative leap from quantitative accumulation, thereby exploring novel methods for drug discovery.

Cell and gene therapy also requires an interdisciplinary approach, encompassing genetics, medicine, molecular biology, virology, bioengineering, chemical engineering, and more. In terms of technical principles, compared with traditional therapies, cell and gene therapyalso demonstrates its advantages. For example, gene therapy refers to the introduction of exogenous genes into target cells via technical means, enabling the treatment of diseases caused by genetic defects or abnormalities under the action of normal genes. This implies that the core of gene therapy lies in addressing the root cause of diseases——Precisely targeted the abnormal DNA itself.

Based on the significant potential for industrial implementation,AI-driven drug discovery, as well as cell and gene therapy, has also attracted significant capital and corporate participation. According to data from the UK-based research firm Deep Pharma Intelligence, as of the second quarter of 2021, there were approximately 300 companies worldwide leveraging AI technologies for drug discovery, biomarker development, and advanced R&D environments, with more than 880 investment institutions having entered this sector. Meanwhile, the global cell and gene therapy market is also experiencing rapid growth.FromFrom 2016 to 2020, the global market size grew from $50.4 million to $2.075 billion, with a compound annual growth rate (CAGR) of 71.2%.

It is evident that it is precisely through the continuous iteration, innovation, and integration of technology that the biomedical industry has been able to achieve ongoing breakthroughs and attract a growing number of new entrants.

Industrial Synergy Is Key to the Long-Term, Steady Development of the Biopharmaceutical Industry

For the biopharmaceutical industry, industrial synergy is just as crucial as technological cross-disciplinary integration and convergence.

This is because technological innovation does not fall under“Low-hanging fruit” is difficult to harvest, thus requiring substantial talent, funding, and resources, as well as policy support and industrial synergy.

Notably, Nanshan District is home to Shenzhen’s entire citywide80% of the leading research universities and R&D institutions in the biomedical field host multiple Nobel laureate laboratories, such as the Neuron Plasticity Laboratory, and have gathered approximately 167 innovation platforms, including key laboratories, engineering centers, and public technical service platforms, among which 11 are national-level innovation platforms.Such industrial support resources undoubtedly provide fertile ground for the development of innovative technologies.

Additionally,The Nanshan District Government also places great emphasis on independent technological innovation.For instance, by strategically prioritizing the R&D of major innovative drugs, policies provide phased funding support for independently developed innovative biomedical products based on the different R&D stages completed after the enterprise’s registration in Nanshan District, with a maximum annual subsidy per enterpriseRMB 20 million. Enterprises within the jurisdiction are encouraged to establish joint laboratories with local universities in the field of biomedicine to carry out technological research and development and talent cultivation, and they will also receive financial support.

It is not difficult to find that,Nanshan District provides proactive services and fully equipped public resources for innovation and entrepreneurship, making the area a petri dish for biomedical innovation.

In summary, it is not difficult to understand why Nanshan District has been able to frequently produce high-quality innovative enterprises in frontier technology fields such as biomedicine and foster a robust innovation ecosystem.

In the future, with the joint efforts of the government and various industry stakeholders, frontier medical technologies—represented by AI-driven drug discovery and cell and gene therapy—are expected to achieve greater progress, thereby benefiting more people.